Botanix Pharmaceuticals Limited (ASX:BOT)
Botanix Pharmaceuticals Limited (ASX:BOT) is a clinical stage synthetic cannabinoid company developing pharmaceutical products that are underpinned by science and supported by randomised clinical trials.
Botanix Pharmaceuticals has two separate cannabinoid development platforms, dermatology and antimicrobial products, both of which leverage the unique anti-inflammatory, immune modulating and antimicrobial properties of cannabinoids, particularly synthetic cannabidiol.
The Company has an exclusive license to use a proprietary drug delivery system (Permetrex) for direct skin delivery of active pharmaceuticals in all skin diseases. Botanix is developing a pipeline of product candidates that leverage the antimicrobial properties of cannabinoids with recent positive data from its antimicrobial study.
For the dermatology platform, Botanix is well progressed towards initiating its Phase 1b rosacea study in 1H CY2021 and following a successful meeting with the FDA, the Company has confirmed a drug development plan for the BTX 1503 acne program to support registration.